LP
STLNW

LMR Partners’s Starling Oncology Warrant STLNW Stock Holding History

LMR Partners’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,624,856
Closed -$32.5K – 1602
2024
Q3 		$32.5K Buy
+1,624,856
New +$32.2K ﹤0.01% 1094

Other funds holding STLNW

OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LMR Partners's STLNW Position: Q2 2026 in Review

LMR Partners held its Starling Oncology Warrant (STLNW) position steady in Q2 2026 at 1,624,856 shares worth $66.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1391.

LMR Partners first reported a position in STLNW in Q4 2021 and has held it in 18 quarters since. The position peaked at $7.3M in Q1 2022. 12 funds tracked by Wall St. Rank hold STLNW as of Q2 2026.

  • LMR Partners held 1,624,856 shares of Starling Oncology Warrant worth $66.3K as of Q2 2026.
  • LMR Partners left its Starling Oncology Warrant share count unchanged in Q2 2026.
  • Starling Oncology Warrant made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1391 holding.
  • LMR Partners first reported a position in Starling Oncology Warrant in Q4 2021 and has held it in 18 quarters since.
  • LMR Partners's Starling Oncology Warrant position peaked at $7.3M in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.